Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to 3.44%.

  • Immunocore Holdings' EBITDA Margin fell 183700.0% to 3.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.39%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 15.66% for FY2024, which is 8800.0% down from last year.
  • Per Immunocore Holdings' latest filing, its EBITDA Margin stood at 3.44% for Q3 2025, which was down 183700.0% from 3.9% recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' EBITDA Margin ranged from a high of 14.93% in Q3 2024 and a low of 573.78% during Q4 2021
  • Over the past 5 years, Immunocore Holdings' median EBITDA Margin value was 21.75% (recorded in 2022), while the average stood at 104.89%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 5259200bps in 2022, then tumbled by -305500bps in 2024.
  • Over the past 5 years, Immunocore Holdings' EBITDA Margin (Quarter) stood at 573.78% in 2021, then surged by 92bps to 47.86% in 2022, then skyrocketed by 98bps to 0.82% in 2023, then tumbled by -3747bps to 31.36% in 2024, then skyrocketed by 89bps to 3.44% in 2025.
  • Its EBITDA Margin was 3.44% in Q3 2025, compared to 3.9% in Q2 2025 and 6.07% in Q1 2025.